---
title: "Xarelto (rivaroxaban), all indications: Drug interactions questions"
description: "Drug interactions questions on Xarelto (rivaroxaban) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: What drug interactions does Xarelto have? Can Xarelto be taken with aspirin or NSAIDs? 2 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/xarelto/drug-interactions"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Xarelto (rivaroxaban), all indications: Drug interactions questions

Manufacturer: Janssen Pharmaceuticals, Inc.  
Prescribing information: [Xarelto](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf)  
Indication pages: [Nonvalvular atrial fibrillation](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation)

## Drug interactions

<a id="xarelto-drug-interactions"></a>

### What drug interactions does Xarelto have?

> “Rivaroxaban is a substrate of CYP3A4/5, CYP2J2, and the P-gp and ATP-binding 
> cassette G2 (ABCG2) transporters, the latter also known as breast cancer 
> resistance protein (BCRP). Combined P-gp and strong CYP3A inhibitors increase 
> exposure to rivaroxaban and may increase the risk of bleeding. Combined P-gp 
> and strong CYP3A inducers decrease exposure to rivaroxaban and may increase 
> the risk of thromboembolic events.”

Source: [XARELTO: Prescribing information, page 10, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=10)

> “Avoid concomitant administration of XARELTO with known combined P-gp and 
> strong CYP3A inhibitors (e.g., ketoconazole and ritonavir) [see Warnings and 
> Precautions (5.6) and Clinical Pharmacology (12.3)].”

Source: [XARELTO: Prescribing information, page 10, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=10)

> “XARELTO should not be used in patients with CrCl 15 to <80 mL/min who are 
> receiving concomitant combined P-gp and moderate CYP3A inhibitors (e.g., 
> erythromycin) unless the potential benefit justifies the potential risk [see 
> Warnings and Precautions (5.4) and Clinical Pharmacology (12.3)].”

Source: [XARELTO: Prescribing information, page 10, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=10)

> “Avoid concomitant use of XARELTO with drugs that are combined P-gp and strong 
> CYP3A inducers (e.g., carbamazepine, phenytoin, rifampin, St. John’s wort) [see 
> Warnings and Precautions (5.6) and Clinical Pharmacology (12.3)].”

Source: [XARELTO: Prescribing information, page 10, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=10)

<a id="xarelto-aspirin-nsaids"></a>

### Can Xarelto be taken with aspirin or NSAIDs?

> “Coadministration of enoxaparin, warfarin, aspirin, clopidogrel and chronic NSAID 
> use may increase the risk of bleeding [see Clinical Pharmacology (12.3)].
> Avoid concurrent use of XARELTO with other anticoagulants due to increased 
> bleeding risk unless benefit outweighs risk. Promptly evaluate any signs or 
> symptoms of blood loss if patients are treated concomitantly with aspirin, other 
> platelet aggregation inhibitors, or NSAIDs [see Warnings and Precautions (5.2)].”

Source: [XARELTO: Prescribing information, page 10, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=10)

> “In ROCKET AF, concomitant aspirin use (almost exclusively at a dose of 100 mg or 
> less) during the double-blind phase was identified as an independent risk 
> factor for major bleeding. NSAIDs are known to increase bleeding, and bleeding 
> risk may be increased when NSAIDs are used concomitantly with XARELTO.”

Source: [XARELTO: Prescribing information, page 14, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=14)

## Related pages
- [Medical information: Xarelto (rivaroxaban): All indications](https://www.evicenter.com/medical-information/xarelto)
- [Indication](https://www.evicenter.com/medical-information/xarelto/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/xarelto/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/xarelto/safety)
- [Specific populations](https://www.evicenter.com/medical-information/xarelto/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/xarelto/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/xarelto/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/xarelto/access-and-coverage)
